PMGC Holdings (ELAB) Other Accumulated Expenses (2022 - 2026)
PMGC Holdings (ELAB) posted Other Accumulated Expenses of $1.3 million for Q1 2026, up 95.8% sequentially from $642925.0 in Q4 2025, and up 551.11% YoY from $193337.0 in Q1 2025.
PMGC Holdings (ELAB) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Other Accumulated Expenses for 5 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Other Accumulated Expenses rose 551.11% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 551.11% YoY) and the FY2025 annual result came in at $642925.0, up 53.36% from the prior year.
- Other Accumulated Expenses climbed to $1.3 million in Q1 2026 per ELAB's latest filing, from $642925.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $222.7 million in Q3 2023 and troughed at $53355.0 in Q2 2025.
- A 5-year average of $18.8 million and a median of $210543.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses tumbled 99.96% in 2024, then soared 551.11% in 2026.
- Over 5 years, Other Accumulated Expenses stood at $154325.0 in 2022, then sank by 50.02% to $77127.0 in 2023, then surged by 443.54% to $419217.0 in 2024, then jumped by 53.36% to $642925.0 in 2025, then soared by 95.8% to $1.3 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.3 million, $642925.0, and $315097.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 642,925.00 |
| Sep 30, 2025 | 315,097.00 |
| Jun 30, 2025 | 53,355.00 |
| Mar 31, 2025 | 193,337.00 |
| Dec 31, 2024 | 419,217.00 |
| Sep 30, 2024 | 80,368.00 |
| Jun 30, 2024 | 56,127.00 |
| Mar 31, 2024 | 227,749.00 |
| Dec 31, 2023 | 77,127.00 |
| Sep 30, 2023 | 222.68 Mn |
| Dec 31, 2022 | 154,325.00 |